Bilateral ovarian masses, massive ascites, and prior appendectomy: must it be ovarian cancer? ——a case report of pseudomyxoma peritonei 24 years after appendectomy - Top-Institutions - MDSpire

Bilateral ovarian masses, massive ascites, and prior appendectomy: must it be ovarian cancer? ——a case report of pseudomyxoma peritonei 24 years after appendectomy

  • By

  • Sijie Feng

  • Shurui Yang

  • Kaixuan Yang

  • Xiuzhang Yu

  • Xiaoyu Niu

  • May 22, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Gynecologic Oncology
    • Cancer Research

  • #2

    Brigham and Women’s Hospital and Dana-Farber Cancer Institute
    Brigham and Women’s Hospital and Dana-Farber Cancer Institute

    Boston, Massachusetts

    Key Differentiators

    • Obstetrics & Gynecology
    • Oncology

  • #3

    Collaborative Group on Epidemiological Studies of Ovarian Cancer
    Collaborative Group on Epidemiological Studies of Ovarian Cancer

    N/A, N/A

    Key Differentiators

    • Epidemiology

  • #4

    Medical Research Council of Cancer Research UK
    Medical Research Council of Cancer Research UK

    N/A, N/A

    Key Differentiators

    • Cancer Research

  • #5

    University of Washington School of Medicine
    University of Washington School of Medicine

    Seattle, Washington

    Key Differentiators

    • Gynecologic Oncology

Original Source(s)

Bilateral ovarian masses, massive ascites, and prior appendectomy: must it be ovarian cancer? ——a case report of pseudomyxoma peritonei 24 years after appendectomy

  • by Sijie Feng, Shurui Yang, Kaixuan Yang, Xiuzhang Yu, Xiaoyu Niu

  • May 22, 2026

Related Content

An integrative naturopathic oncology approach in metastatic malignant melanoma: two case reports

Trends in liver failure-related mortality among middle-aged and older adults with digestive system malignant tumors in the United States, 1999–2023

Venetoclax combined with azacitidine in the treatment of secondary myelodysplastic syndrome following multiple myeloma: a case report and literature review